PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors
Stopped early · Phase 1
Conditions studied: Advanced Solid Tumors, Gastric Cancer, Gastroesophageal Junction Cancer, Urothelial Cancer, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinomas
In brief
The purpose of this study is to assess the safety and effects of PF-07265028 as monotherapy and in combination with sasanlimab. The study aims to identify the maximum tolerated dose (MTD) of PF-07265028 as monotherapy; evaluate the clinical activity of monotherapy and combination; and select the recommended dose of PF-07265028 monotherapy and in combination for potential further studies and development. The study contains 2 parts, Dose Escalation (Part 1) to determine the recommended dose of PF-07265028 as single agent and in combination, followed by Dose Expansion (Part 2) in selected tumor types at the recommended dose. It is expected that most participants will take part in this study for up to 1 year with six on-site visits in the first month and then at least twice every subsequent month while they are on treatment.
Key facts
- Study ID
- NCT05233436
- Run by
- Pfizer
- People needed
- 21
- Starts
- 2022-02-24
- Expected to finish
- 2023-10-16
- Last updated by the study team
- 2026-02-19
Who can join
Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.
Where it is running
- HonorHealth Research Institute — Scottsdale, Arizona, United States
- HonorHealth Scottsdale Shea Medical Center — Scottsdale, Arizona, United States
- University of Iowa — Iowa City, Iowa, United States
- START Midwest — Grand Rapids, Michigan, United States
- Mary Crowley Cancer Research — Dallas, Texas, United States
- South Texas Accelerated Research Therapeutics, LLC — San Antonio, Texas, United States
- National Cancer Center Hospital East — Kashiwa, Chiba, Japan
- The Cancer Institute Hospital of JFCR — Koto, Tokyo, Japan
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.